Treatment of elderly patients with ischemic stroke

Effects of Anti-CD20 monoclonal antibody on immunologic factors in elderly patients with ischemic stroke

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20160422027520N11

Enrollment

Registered

2019-03-07

Start date

2019-05-20

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elderly patients with ischemic stroke. Ischemic Stroke

Interventions

Intervention 1: Intervention group: Elderly patients with ischemic stroke who received the anti-CD20 monoclonal antibody. Intervention 2: Control group: Elderly people with ischemic stroke are not rec

Eligibility

Sex/Gender

All

Age

60 Years to 75 Years

Inclusion criteria

Inclusion criteria: Willingness to cooperate Aged 60 to 75 years Diagnosis of ischemic stroke by a neurologist Radiological findings (MRI, CT) consistent with clinical diagnosis of ischemic stroke NIHSS score between 6 and 22

Exclusion criteria

Exclusion criteria: Use of nutritional supplements and antioxidant and alpha-lipoic acid during a month before the study History of diabetes, high or low blood pressure and other chronic diseases (kidney, lung disorders, etc.), anemia, thrombocytopenia A history of autoimmune diseases, immunodeficiency diseases, asthma and allergies Cancer Viral infections (hepatitis B, influenza ...) Occurrence of recurrence of disease during the study Evidence from CT or MRI based on acute or chronic intracerebral hemorrhage, arteriovenous malformation (AVM), Subarachnoid hemorrhage (SAH) brain aneurysm or tumor. Symptoms or signs of neurology that quickly recover during screening and are likely to recover completely within 24 hours. Not wanting to continue cooperation

Design outcomes

Primary

Measure	Time frame
Determination of Frequency of CD20 + B Cells in Elderly People with Ischemic Stroke in the Group Receiving Anti-CD20 Antibody and Control Group. Timepoint: After 24 hours of stroke in acute phase. Method of measurement: Flow cytometry.;Determination of the frequency of Th1 and Th17 cells in the elderly with ischemic stroke in the group receiving Anti-CD20 Antibody and Control Group. Timepoint: After 24 hours of stroke in acute phase. Method of measurement: Flow cytometry.;Determination of the expression of gene expression of effective transcription factors in the development of Th1 and Th17 cells in the elderly with ischemic stroke in the group receiving Anti-CD20 Antibody and Control Group. Timepoint: After 24 hours of stroke in acute phase. Method of measurement: Quantitative Real time PCR.;Determination of the expression of cytokine genes from Th1 and Th17 cells in the elderly with ischemic stroke in the group receiving Anti-CD20 Antibody and Control Group. Timepoint: After 24 hours of stroke in acute phase. Method of measurement: Quantitative Real time PCR.;Determination of the secretion of cytokines secreted from Th1 and Th17 cells in the elderly with ischemic stroke in the group receiving Anti-CD20 Antibody and Control Group. Timepoint: After 24 hours of stroke in acute phase. Method of measurement: Quantitative Real time PCR.	—

Measure

Time frame

Determination of Frequency of CD20 + B Cells in Elderly People with Ischemic Stroke in the Group Receiving Anti-CD20 Antibody and Control Group. Timepoint: After 24 hours of stroke in acute phase. Method of measurement: Flow cytometry.;Determination of the frequency of Th1 and Th17 cells in the elderly with ischemic stroke in the group receiving Anti-CD20 Antibody and Control Group. Timepoint: After 24 hours of stroke in acute phase. Method of measurement: Flow cytometry.;Determination of the expression of gene expression of effective transcription factors in the development of Th1 and Th17 cells in the elderly with ischemic stroke in the group receiving Anti-CD20 Antibody and Control Group. Timepoint: After 24 hours of stroke in acute phase. Method of measurement: Quantitative Real time PCR.;Determination of the expression of cytokine genes from Th1 and Th17 cells in the elderly with ischemic stroke in the group receiving Anti-CD20 Antibody and Control Group. Timepoint: After 24 hours of stroke in acute phase. Method of measurement: Quantitative Real time PCR.;Determination of the secretion of cytokines secreted from Th1 and Th17 cells in the elderly with ischemic stroke in the group receiving Anti-CD20 Antibody and Control Group. Timepoint: After 24 hours of stroke in acute phase. Method of measurement: Quantitative Real time PCR.

—

Secondary

Measure	Time frame
Determination of infarction brain tissue in elderly patients with ischemic stroke in the group receiving monoclonal antibodies anti-antigen CD20 and control group. Timepoint: One month after receiving the drug. Method of measurement: MRI?CT scan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehdi Yousefi

Tabriz University of Medical Sciences

Yousefime@tbzmed.ac.ir+98 41 3336 4665

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026